Alcon gets FDA OK for Travatan Z glaucoma solution

By Elaine Rigoli

Tampa, Fla., Sept. 22 - The Food and Drug Administration has approved Alcon, Inc.'s Travatan Z (travoprost ophthalmic solution) 0.004% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant of or insufficiently responsive to other intraocular pressure lowering medications.

The Fort Worth, Texas-based eye-care company said Travatan Z is a new formulation that eliminates benzalkonium chloride from Alcon's existing Travatan solution and replaces benzalkonium chloride with Sofzia, a robust ionic buffered preservative system that is gentle to the ocular surface.

Alcon developed this benzalkonium chloride-free version of Travatan because long-term use of topical solutions containing benzalkonium chloride may compromise the ocular surface and exacerbate conditions such as dry eye, according to a news release.

FDA approval of Travatan Z solution was based on a double-masked, multi-center study of 690 adult patients with open-angle glaucoma or ocular hypertension, randomized to receive Travatan or Travatan Z.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.